Taysha Gene Therapies (TSHA) Current Assets (2019 - 2026)

Taysha Gene Therapies has disclosed Current Assets across 8 years of filings, most recently posting $282.2 million for Q1 2026.

• Current Assets for Q1 2026 came in at $282.2 million, up 133.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $282.2 million (up 133.83% YoY), and the FY2025 annual result was $324.6 million, up 128.42% from the prior year.
• Current Assets came in at $282.2 million for Q1 2026 at Taysha Gene Therapies, down from $324.6 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $324.6 million in Q4 2025 to a low of $43.0 million in Q3 2022.
• The 5-year median for Current Assets is $142.1 million (2024), against an average of $160.5 million.
• Across the five-year window, Current Assets sank 78.19% in 2022 and jumped 299.53% in 2023, its largest moves.
• Taysha Gene Therapies' Current Assets stood at $96.4 million in 2022, then surged by 55.44% to $149.9 million in 2023, then declined by 5.16% to $142.1 million in 2024, then surged by 128.42% to $324.6 million in 2025, then declined by 13.06% to $282.2 million in 2026.
• The last three Current Assets figures came in at $282.2 million (Q1 2026), $324.6 million (Q4 2025), and $300.0 million (Q3 2025), per Business Quant data.